Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC)

Plain Language SummaryWhat is this summary about?This summary describes the results of a clinical study called TASUKI-52. This study aimed to see if combining a medicine called nivolumab with a cytotoxic chemotherapy plus bevacizumab could help people with a type of lung cancer called nonsquamous non-small cell lung cancer (NSCLC). The researchers looked at how long people lived without their cancer getting worse, how long people lived overall, and what side effects people had. The study included a total of 550 people with nonsquamous NSCLC whose cancer was advanced (meaning it had spread far from its original location in the body) or recurrent (meaning it had come back or gotten worse again after being treated previously). Of these, 273 people received nivolumab with chemotherapy plus bevacizumab and 275 people received placebo (an inactive substance given instead of an active medicine) with chemotherapy plus bevacizumab.The purpose of adding nivolumab is to help the immune system (the body’s natural defenses) target and kill cancer cells. The researchers also looked at the cancer cells’ expression of PD-L1 (programmed cell death ligand 1), which is a protein that helps cancer cells hide from the immune system, because its expression level can vary among individuals and might affect the effectiveness of treatment with nivolumab.What are the key takeaways?On average, people in the nivolumab group lived longer without their disease getting worse compared with people in the placebo group. People in the nivolumab group also lived longer overall, regardless of the cause of death. When the researchers looked at the long-term effects of treatment over a 3-year period, the survival benefits of nivolumab persisted and did not depend on the cancer cells’ expression of PD-L1. The side effects of nivolumab were similar to those reported in previous studies.What were the main conclusions reported by the researchers?Adding nivolumab to chemotherapy plus bevacizumab improved the long-term survival of people with this type of lung cancer regardless of the cancer cells’ PD- L1 expression. The addition of nivolumab to chemotherapy plus bevacizumab did not cause a large number of serious side effects.Clinical trial number: NCT03117049